MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, IOBT had $2,788K increase in cash & cash equivalents over the period. -$18,482K in free cash flow.

Cash Flow Overview

Change in Cash
$2,788K
Free Cash flow
-$18,482K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-8,378 -48,638
Depreciation
61 125
Equity-based compensation
1,476 3,176
Non-cash interest expense
886 253
Amortization of right of use lease asset
169 336
Foreign currency loss (gain)
98 -479
Change in fair value of warrants
-9,846 2,587
Prepaid expenses and other current assets
975 636
Other non-current assets
13 882
Accounts payable
50 877
Lease liability
-139 -418
Accrued expenses and other current liabilities
-1,671 -152
Net cash used in operating activities
-18,478 -42,893
Purchase of property and equipment
4 54
Net cash used in investing activities
-4 -54
Proceeds from the issuance of debt
14,714 11,720
Payments of debt issuance costs
18 233
Proceeds from issuance of common stock upon exercise of stock options
2 -
Proceeds from issuance of common stock in connection with at-the-market program, net of issuance costs of 134
6,572 -
Net cash provided by financing activities
21,270 11,487
Net decrease in cash, cash equivalents and restricted cash
2,788 -31,460
Effect of exchange rate changes on cash
-695 -
Cash and cash equivalents at beginning of period
60,299 -
Cash and cash equivalents at end of period
30,932 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

IO Biotech, Inc. (IOBT)

IO Biotech, Inc. (IOBT)